Specialised Services clinical commissioning policies and service specification - 3rd Wave

Overview

NHS England has today (12 February 2016) launched a 30 day public consultation on a proposed number of new products for specialised services, (including service specifications and clinical commissioning policies). There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicans and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the specifications and policies to date. Please note this is one of several public consultations on a proposed number of new draft products for specialised services. We now wish to test them further with wider groups of stakeholders.

Related documents

Clinical Commissioning Policies
 

Ivacaftor for children aged 2-5 years with cystic fibrosis (named mutations):

• Policy Proposition
• Evidence Review
• Impact Assessment Report
• Clinical Panel Report
• Stakeholder Engagement Report

Continuous aztreonam lysine for cystic fibrosis (all ages):

• Policy Proposition
• Evidence Review
• Impact Assessment Report
• Clinical Panel Report
• Stakeholder Engagement Report

Rituximab for the treatment of dermatomyositis and polymyositis (Adults):

• Policy Proposition
• Evidence Review
• Impact Assessment Report
• Clinical Panel Report
• Stakeholder Engagement Report

Auditory brainstem implant with congenital abnormalities of the auditory nerves or cochleae:

• Policy Proposition
• Evidence Review
• Impact Analysis Report
• Clinical Panel Report
• Stakeholder Engagement Report